Emerging melanoma therapeutics: IDO1, LAG-3 & HDAC inhibitors

Emerging melanoma therapeutics: IDO1, LAG-3 & HDAC inhibitors

VJOncology

1 year
177 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
A variety of new therapeutics for melanoma are on the horizon, including IDO, immune checkpoint, LAG-3 and HDAC inhibitors. Here, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, discusses some of these exciting developments. He reflects upon the results from the KEYNOTE-252 trial (NCT02752074) of the IDO1 inhibitor epacadostat with the checkpoint inhibitor pembrolizumab, before moving onto the exciting combination of nivolumab with anti-LAG-3 antibody relatlimab (NCT02966548). Dr Ascierto also highlights the combination of HDAC inhibitor entinostat with pembrolizumab (NCT02437136). He then discusses potential avenues for the future, including triplet regimens, referencing preclinical data. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Up Next Autoplay
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
20 Views
Cancer-News 1 week
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
23 Views
Cancer-News 1 month
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
11 Views
moasc 2 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
10 Views
moasc 2 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
3 Views
moasc 2 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
6 Views
moasc 2 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
2 Views
moasc 2 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
1 Views
moasc 2 months
IMNC Data
IMNC Data
Category: Melanoma and Skin Cancer
4 Views
moasc 2 months
Follow up on The Long-Term Checkmake-004 in Metastatic Melanoma
Follow up on The Long-Term Checkmake-004 in Metastatic Melanoma
Category: Melanoma and Skin Cancer
20 Views
obr 4 months